The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1517
Triferic for Iron Replacement
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ferric pyrophosphate citrate solution (Triferic – Rockwell Medical) to maintain hemoglobin concentrations in adults with hemodialysis-dependent chronic kidney disease. Triferic is the first iron replacement product that is added into the hemodialysis solution at each dialysis procedure.

IRON SUPPLEMENTATION — Iron deficiency anemia is common in patients with chronic kidney disease who require hemodialysis; contributing factors include gastrointestinal bleeding, blood draws, use of erythropoiesis-stimulating agents (ESAs), and hemodialysis itself. In these patients, IV iron is preferred over oral iron for supplementation because oral formulations are poorly absorbed.1 IV iron preparations approved for use in patients requiring hemodialysis include iron dextran (Dexferrum; INFeD), sodium ferric gluconate (Ferrlecit, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Triferic for Iron Replacement
Article code: 1517e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian